ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2007 Annual Meeting

Click here to go to the previous page

GU I - Late Toxicity After Treatment for Prostate Cancer

Track : Scientific Sessions

Program Code: SS-B

Date: Monday, October 29, 2007

Time: 10:15 AM to 11:45 AM EST

Duration: 230 Minutes

Location: 502

ABSTRACT PRESENTER(S):

Click the plus sign to see more detailed information about each speaker.

Mark Buyyounouski, Assistant Professor, Fox Chase Cancer Center

M. Cheung, M.D., M.D. Anderson Cancer Center, Houston, TX

Jeff Michalski, Vice Chairman and Director for Clinical Programs, Washington University Medical Center

Julian Moore, D.O., Mount Sinai School of Medicine, New York, NY

Reshma Munbodh, Ph.D., Memorial Sloan-Kettering Cancer Center, New York, NY

Navesh Sharma, D.O., Ph.D., Fox Chase Cancer Center, Philadelphia, PA

William Shipley, Professor, Massachusetts General Hospital

William U. Shipley, M.D., F.A.C.R., completed his medical degree at Harvard Medical School in 1966. After internship and 2 years of surgical residency at the Massachusetts Genera Hospital, he trained in Radiation Oncology at the Harvard Joint Center and then was in London for one year on the HMS Moseley Fellowship. He currently is the Andres Soriano Professor of Radiation Oncology at the Harvard Medical School and the Head of Genito-Urinary Oncology in the Department of Radiation Oncology at the Massachusetts General Hospital. After joining the staff at Massachusetts General Hospital in 1974, Dr. Shipley became a leader in clinical research in the area of genitourinary oncology evaluating multi-modality cancer care. He entered into a very special cooperation with his MGH colleagues in urology, in medical oncology, in radiation oncology and in pathology resulting in the implementation of seven successive national protocols for muscle-invading bladder cancer patients using a multi-modality approach which allowed over two thirds of those patients so-treated to escape without receiving radical bladder-removing surgery. In prostate cancer Professor Shipley helped develop and lead 10 randomized clinical trials using radiation therapy evaluating the advantages of high dose proton beam irradiation and evaluating in the National Radiation Group, the RTOG, the benefits of combining androgen deprivation with radiation in men with localized prostatic cancer. Professor Shipley, who holds many national and international leadership positions on committees and consensus panels in genitourinary oncology, has also chaired the American Society for Radiation Therapy and Oncology committee that has developed International educational courses with the local radiation oncology societies of emerging countries.

Susan Tucker, Ph.D., U.T.M.D. Anderson Cancer Center, Houston, TX

Riccardo Valdagni, M.D., Fondazione IRCCS Istituto Nazionale Tumori, Milan 20133

MODERATOR(S):

Mitchell Anscher, M.D., Virginia Commonwealth Medical Center, Richmond, VA

Ronald Ennis, Director, St. Lukes-Roosevelt

Streaming Audio with
PowerPoint Slides

(Code: SS-B)

Member-in-Training:

List Price:

Member-in-Training:

Member:

Members/Attendees Login

This session is a part of:

Full Web Based Compilation